LSLisa Spring

Lisa Spring

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lisa Spring has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315)

    by Martin Stuschke, Michael Thomas, Andreas Gröschel, Martin Sebastian, Martin Reck, Petra Hoffknecht, Christian Grah, Lisa Spring, Martina Jänicke, Carolin Lennartz, et al.

    Background/Objectives: Following findings of the PACIFIC trial, consolidation therapy with durvalumab was established as standard of care for patients with unresectable, stage III non-small cell lung cancer (NSCLC) and no disease progression after chemoradiotherapy (CRT). This study evaluated real-world effectiveness of durvalumab consolidation in clinical routine in Germany. Methods: Patients with unresectable, stage III NSCLC enrolled in the prospective, multicenter CRISP registry (August 2018–June 2023) were classified into two subgroups: treated with/without durvalumab consolidation therapy. Following stabilized inverse probability of treatment weighting, progression-free survival (PFS) and overall survival (OS) were assessed. Results: This analysis included 231 patients, 124 with and 107 without durvalumab consolidation therapy. In the two subgroups (with/without durvalumab), median age was 67.2/64.6 years, 51.6%/47.7% were female, and 83.1%/86.0% had Eastern Cooperative Oncology Group performance status ≤1. Most patients (87%) received concurrent CRT. In the weighted analysis, median PFS was significantly longer with durvalumab consolidation (18.6 months, 95% CI [12.8, 24.5] vs. 7.5 months, 95% CI [5.5, 8.4]; HR 0.52, 95% CI [0.37, 0.73]); median OS was numerically longer but did not reach statistical significance (34.4 months, 95% CI [25.4, not available/not reached] vs. 27.5 months, 95% CI [17.4, 59.6]; HR 0.67, 95% CI [0.44, 1.02]). Conclusions: This real-world study confirmed significant PFS improvements with durvalumab consolidation in unresectable, stage III NSCLC, with effect sizes comparable to PACIFIC. Although OS differences were not statistically significant, these findings provide valuable real-world evidence supporting the effectiveness of durvalumab consolidation in routine clinical practice.

  • Open Access

    Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer – final results from the prospective German TLK cohort study

    by Ulla von Verschuer, Roland Schnell, Hans Werner Tessen, Jochen Eggert, Adrian Binninger, Lisa Spring, Martina Jänicke, Norbert Marschner


  • Open Access

    Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer – Results from the prospective German Tumour Registry Breast Cancer cohort study

    by Jan Schröder, Thomas Fietz, Andreas Köhler, Volker Petersen, Hans Tesch, Lisa Spring, Annette Fleitz, Martina Jänicke, Norbert Marschner


  • Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): A prospective German registry in stage IV NSCLC AIO-TRK-0315.

    by Frank Griesinger, Wilfried Ernst Erich Eberhardt, Norbert Marschner, Martina Jänicke, Lisa Spring, Joerg Sahlmann, Aysun Karatas, Annette Hipper, Martin Sebastian, Michael Thomas

    TPS9108 Background: Treatment in NSCLC is quickly evolving. Whether outcome and PRO data generated in clinical trials with narrow inclusion and exclusion criteria will hold up in the routine practice is of high interest, especially due to the increasing costs of new drugs. Therefore registry data are of increasing importance to patients, physicians and third parties. This is why we have started a prospective, clinical registry for patients with metastatic non-small cell lung cancer. Methods: The purpose of CRISP is to set up a national clinical research platform to document representative data on molecular testing, sequences of therapies and other treatment modalities, course of disease in patients with advanced or metastatic NSCLC not amenable to curative treatment. A particular focus is on molecular biomarker testing of patients before the start of first-line treatment. PRO assessment will provide large-scale data on quality of life and anxiety/depression for real-life patients in routine practice. In addition, two questionnaires (concerning individual quality of life and patient-caregiver communication) will be validated in German patients with metastatic NSCLC. Furthermore CRISP will set up a decentral tissue annotation for future collaborative, investigational scientific biomarker testing. This study will be carried out in up to 150 representative cancer centers in all therapeutic sectors in Germany. More than 5000 patients will be recruited and followed up to a maximum of 3 years, respectively until death. The first patients have been included as of December 2015. Preliminary data will be presented at the meeting in terms of molecular test rates, demographic data as well as treatment stratification in the 1st line setting. In conclusion: The registry CRISP will be the first to present representative real life data, covering all treatment settings of patients with NSCLC in Germany. ClinicalTrials.gov Identifier: NCT02622581. CRISP is supported by Grants from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Merck Sharp & Dohme, Novartis, and Pfizer. Clinical trial information: NCT02622581.